nedisertib
Small moleculeexperimental
Clinical trial activity
9 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2014 (NCT02316197)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Ovarian Epithelial · Phase 1
- Cholangiocarcinoma · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Gallbladder Neoplasms · Phase 1/Phase 2
- Glioblastoma · Phase 1
- Gliosarcoma · Phase 1
- Hamartoma · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Neoplasm Metastasis · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 1/Phase 2
Mechanism of action
- DNA-dependent protein kinaseINHIBITOR
PRKDC inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc([C@@H](O)c2cc(-c3ncnc4cc(N5CCOCC5)ccc34)c(F)cc2Cl)nn1- Mol. weight
- 481.92 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297629 ↗
Also known as
- msc2490484a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04555577 | Phase 1 | Sep 20, 2020 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT04172532 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2020 | Johns Hopkins University, National Cancer Institute (NCI) |
| NCT04266912 | Phase 1/Phase 2 (Phase 2) | Mar 31, 2020 | University of Texas at Houston |
| NCT04092270 | Phase 1 | Mar 6, 2020 | Johns Hopkins University, National Cancer Institute (NCI) |
| NCT04071236 | Phase 1/Phase 2 (Phase 2) | Dec 27, 2019 | National Cancer Institute (NCI), Yale University |
| NCT04068194 | Phase 1/Phase 2 (Phase 2) | Oct 4, 2019 | National Cancer Institute (NCI) |
| NCT03983824 | Phase 1 | Oct 4, 2019 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT02516813 | Phase 1 | Sep 1, 2015 | Merck KGaA, Merck Serono |
| NCT02316197 | Phase 1 | Dec 31, 2014 | Merck KGaA |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 6 | 5 | 2 | 2019 |
| Johns Hopkins University | Academic/Hospital | 2 | 0 | 2 | 2020 |
| Merck KGaA | For profit | 2 | 1 | 1 | 2014 |
| University of Texas at Houston | Academic/Hospital | 2 | 2 | 2 | 2020 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Merck Serono | For profit | 1 | 1 | 1 | 2015 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2019 |
7 organizations
Page 1 / 1